Prospective Research in Memory Clinics (PRIME)
28 de novembro de 2013 atualizado por: Janssen-Cilag Pty Ltd
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia.
Approximately 4500 patients will be enrolled in this disease registry across 12 sites in Australia.
Clinical, treatment, health status and economic data will be acquired over 3 years.
The study will identify the relationships among demographic variables, prognostic features, geographic setting, treatment options and clinical, economic and health status (activities of daily living and caregiver impact) outcomes.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
A complete record of patient care will be collected to provide detailed information on the management and outcome of mild cognitive impairment and dementia and the profile of patients at participating sites.
The data will be used to build models looking at the effect of management of these conditions on principal clinical events, health status and economic outcomes.
This will provide the foundation for subsequent objective and prospective evaluation of evidence-based strategies for the optimal treatment of mild cognitive impairment and dementia in Australia.
This study is not prescriptive, but will instead examine the influence of a whole range of routinely used management strategies on clinical and economic outcomes among mild cognitive impaired and dementia patients in Australia.
This 'practice based' approach is increasingly widely used and is a useful tool for elucidating the relative effectiveness of different management strategies and for exploring relationships between patient characteristics, treatment and outcomes.
Observational study - no study drug administered.
Tipo de estudo
Observacional
Inscrição (Real)
970
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Chermside N/A, Austrália
-
Fremantle, Austrália
-
Geelong, Austrália
-
Heidelberg, Austrália
-
Hornsby, Austrália
-
Kew, Austrália
-
Newcastle, Austrália
-
Randwick, Austrália
-
Woodville, Austrália
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Método de amostragem
Amostra Não Probabilística
População do estudo
Consenting patients with mild cognitrive impairement or dementia recruited at 12 participating sites accross Australia.
Descrição
Inclusion Criteria:
- Diagnosis of dementia under the DSM-IV criteria, or of Mild Cognitive Impairment, using the Peterson Criteria
- Living in the community (home, apartment or collective housing with nursing care available for less than 40 hours per week)
- Patient able to provide written informed consent, or provision of written informed consent by a legal guardian/proxy
- Availability of a caregiver willing to provide consent for required components of the study
- Fluent in English
- May be participating in a Phase IV or other post-marketing follow up study of an approved product for treatment of dementia
Exclusion Criteria:
- No concomitant life-threatening illness (a condition which is likely to interfere with the patient's ability to complete the study)
- Not unwilling or unable to complete the study
- Not concurrently participating in a clinical trial of an investigational drug (phase I, II or III)
- Unwillingness of patient or legal guardian / proxy to provide written informed consent
- Unwillingness of caregiver to provide written informed consent
- For patients with diagnosis of mild cognitive impairment: current or previous treatment with any cholinesterase or memantine
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: Coorte
- Perspectivas de Tempo: Prospectivo
Coortes e Intervenções
Grupo / Coorte |
Intervenção / Tratamento |
|---|---|
|
Mild cognitive impairment or dementia
Patients with mild cognitive impairment or dementia.
|
Patients will be observed for the evaluation of current management strategies.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
The primary objective of the study is to analyse the epidemiology and treatment outcomes of mild cognitive impairment and dementia under conditions of routine clinical practice
Prazo: 6 months, 12 months and 36 months
|
6 months, 12 months and 36 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Clinical Dementia Rating Scale (total and overall score)
Prazo: Baseline, 3, 6, 12, 24, and 36 months
|
CDR is a 5-point scale to evaluates the clinical patterns and severity of the patients suspected or diagnosed as dementia in 6 areas: memory, orientation, judgment and problem solving ability, social activity, domestic living and hobbies, and hygiene and dressing up, where 0 = no cognitive impairment, 0.5 = very mild dementia, 1 = mild, 2 = moderate, and 3 = severe.
Higher scores indicate worsening.
|
Baseline, 3, 6, 12, 24, and 36 months
|
|
Mini Mental State Examination (total score)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
The mini-mental state examination (MMSE) is a brief 30-point questionnaire test that is used or the assessment of dementia patients' cognitive impairment.
Evaluation of points are as follows: 24 to 30 = no cognitive impairment, 18 to 23 = mild cognitive impairment, 0 to 17 = severe cognitive impairment.
Lower scores indicate worsening.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
The Alzheimer's Disease Assessment Scale (cognitive total score)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
Alzheimer's Disease Assessment Scale is consists of 11 items, which assess memory, language and praxis, and can be administered independently of the non-cognitive portion.
The total score ranges between 0 (best) and 70 (worst), with eight of the eleven items scoring between 0 (no impairment) and 5 (most impairment), and three of the items scoring from 0 to 8 (orientation questions), 0 to 10 (word recall) and 0 to 12 (word recognition).
Higher scores indicate worsening
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
The Clock Drawing Test (total score)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
The Clock Drawing Test is a simple and reliable measure of visuospatial ability.
The test requires the participant to draw the face of a clock reading ten minutes after eleven, and the rater scores the result from 10 (best) to 1 (worst).
Lower scores indicate worsening.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
Frontal Assessment Battery (total score)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
Frontal Assessment Battery is a short, simple testing for frontal lobe function that explores six domains of frontal lobe activity; conceptualization, mental flexibility, motor programming, sensitivity to interference, inhibitory control, and environmental autonomy.
It takes approximately 10 minutes to administer.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
Functional Autonomy Measurement System (total score and subscores)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
Functional Autonomy Measurement System is a 29-item scale developed according to the WHO classification of disabilities.
It measures functional ability in five areas: activities of daily living (ADL), mobility, communication, mental functions and instrumental activities of daily living (IADL).
For each item, the disability is scored on a 5-point scale: 0 (independent), -0.5 (with difficulty), -1 (needs supervision), -2 (needs help), -3 (dependent).
A disability score (up to -87) can be calculated, together with sub-scores for each dimension.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
Neuropsychiatric Inventory (total score, total distress to caregivers score, and total number of behaviors)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
The neuropsychiatric inventory is used to characterize the neuropsychiatric symptom profiles in a variety of neurological diseases.
Categories include symptoms like delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability, apathy, Night-time behaviour, appetite and eating, and aberrant motor activity.
For each symptom, responder has to indicate "yes", if the symptom has been present since a month.
The responder then rate the severity of the symptom on a 3-point scale for which scores range from "1 = Mild (noticeable, but not a significant change)" to "3 = Severe (very marked or prominent; a dramatic change)" and also rate the distress experienced due to the symptom on a 6-point scale for which scores range from "0 = Not distressing at all" to "5 = Extreme or very severe (extremely distressing, unable to cope with)".
Higher scores indicate more behavioural disturbance.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
Zarit caregiver burden interview (total score)
Prazo: Baseline, 3, 6, 12, 24 and 36 months
|
Zarit caregiver burden scale is used to measure caregiver burden as it relates to time, developmental comparison with peers, physical health, social relationships, and emotional health.
It has 22 item and each question is scored on a 5-point Likert scale ranging from 0 = never present to 4 = nearly always present.
The sum of the total scores of the 22-items is calculated in the range from 0 (low burden) to 88 (high burden).
Higher scores indicate worsening.
|
Baseline, 3, 6, 12, 24 and 36 months
|
|
Resource Utilization
Prazo: Every month up to 36 months
|
Resource utilization questionnaire will be completed at the end of each calendar month by participant/caregiver.
|
Every month up to 36 months
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Links úteis
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2005
Conclusão Primária (Real)
1 de agosto de 2011
Conclusão do estudo (Real)
1 de agosto de 2011
Datas de inscrição no estudo
Enviado pela primeira vez
24 de fevereiro de 2006
Enviado pela primeira vez que atendeu aos critérios de CQ
24 de fevereiro de 2006
Primeira postagem (Estimativa)
28 de fevereiro de 2006
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
2 de dezembro de 2013
Última atualização enviada que atendeu aos critérios de controle de qualidade
28 de novembro de 2013
Última verificação
1 de novembro de 2013
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CR004819
- GALDEM4007 (Outro identificador: Janssen-Cilag Pty Ltd, Australia)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
produto fabricado e exportado dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .